Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Antiretrovirus Agent
5%
Cabotegravir
23%
Clinical Trial
14%
Dapivirine
22%
Drug Concentration
9%
Emtricitabine
21%
Fumaric Acid
7%
Glycerol
5%
HIV
100%
Human Immunodeficiency Virus Infection
20%
Implant
8%
Infection
9%
Levonorgestrel
6%
Maraviroc
9%
Microbicide
7%
Pharmacodynamics
15%
Pharmacokinetics
56%
Placebo
17%
Randomized Controlled Trial
5%
Rifapentine
5%
Tenofovir
53%
Tenofovir Alafenamide
11%
Tenofovir Disoproxil
20%
Tolerability
8%
Keyphrases
Adverse Events
6%
AIDS/HIV
11%
Antiretroviral
5%
Antiviral Drugs
9%
Cabotegravir
15%
Cisgender
7%
Dapivirine
14%
Dapivirine Vaginal Ring
7%
Drug Concentration
7%
Emtricitabine
13%
Fumarate
6%
HIV Infection
9%
HIV Patients
11%
HIV Pre-exposure Prophylaxis
20%
HIV Prevention
5%
HIV Research Network
14%
Human Immunodeficiency Virus Infection
6%
Human Immunodeficiency Virus Prevention
5%
Human Immunodeficiency Virus Type 1 (HIV-1)
12%
Long-acting Cabotegravir
7%
Long-acting Injectable
7%
Maraviroc
9%
Men Who Have Sex with Men
6%
Oral Pre-exposure Prophylaxis
7%
Pharmacodynamics
8%
Pharmacokinetic Study
5%
Pharmacokinetics
26%
Placebo
6%
Pre-exposure Prophylaxis (PrEP)
38%
Safety Study
5%
Tenofovir
27%
Tenofovir Alafenamide
8%
Tenofovir Diphosphate
7%
Tenofovir Disoproxil Fumarate
17%
Tolerability
6%
Transgender
9%
United States
5%
Vaginal Ring
10%
Medicine and Dentistry
Cabotegravir
13%
Dapivirine
8%
Human Immunodeficiency Virus
39%
Human Immunodeficiency Virus Infection
8%
Infection
5%
Pharmacokinetics
12%
Placebo
8%
Pre-Exposure Prophylaxis
13%
Tenofovir
9%
Vagina Ring
9%